In a 2025 study by Dobrilovic et al. [28], 487 PAD patients with advanced PAD were followed one year after endovascular revascularization to analyze the value of preprocedural hs-cTnI levels in predicting all-cause mortality or non-fatal ischemic events. This evidence concerns the gene TNNI3 and peripheral arterial disease.